Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accumulated Expenses (2016 - 2017)

Northwest Biotherapeutics' Accumulated Expenses history spans 8 years, with the latest figure at $933000.0 for Q1 2017.

  • Quarterly results put Accumulated Expenses at $933000.0 for Q1 2017, down 21.53% from a year ago — trailing twelve months through Mar 2017 was $933000.0 (down 21.53% YoY), and the annual figure for FY2016 was $901000.0, down 31.17%.
  • Accumulated Expenses for Q1 2017 was $933000.0 at Northwest Biotherapeutics, up from $901000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.3 million in Q2 2016 to a low of $655000.0 in Q2 2014.
  • The 5-year median for Accumulated Expenses is $1.1 million (2013), against an average of $1.0 million.
  • The sharpest move saw Accumulated Expenses tumbled 85.71% in 2013, then skyrocketed 81.37% in 2015.
  • Year by year, Accumulated Expenses stood at $842000.0 in 2013, then skyrocketed by 43.82% to $1.2 million in 2014, then grew by 8.09% to $1.3 million in 2015, then crashed by 31.17% to $901000.0 in 2016, then rose by 3.55% to $933000.0 in 2017.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $933000.0, $901000.0, and $1.3 million for Q1 2017, Q4 2016, and Q3 2016 respectively.